Kamada Ltd. (KMDA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates solid financial performance with increased revenues, net income, and EBITDA. Positive guidance, ongoing product launches, and strategic initiatives like M&A and plasma expansion further bolster growth prospects. While some uncertainties exist (e.g., CMV study specifics), the overall sentiment is positive, supported by strong financials and strategic plans.
Key Financial Performance
Total Revenues (First 9 Months of 2025) $135.8 million, representing an 11% year-over-year increase. The growth was primarily due to increased sales of GLASSIA in ex-U.S. markets, increased sales in the distribution segment, and VARIZIG sales in the U.S. market.
Adjusted EBITDA (First 9 Months of 2025) $34.2 million, up 35% year-over-year, representing a 25% margin of revenues. This increase reflects the overall improvement in product sales mix and commercial scale.
Total Revenues (Third Quarter of 2025) $47 million, up 13% compared to $41.7 million in the third quarter of 2024. The increase was driven by the diversity of the product portfolio and increased sales of GLASSIA and VARIZIG.
Gross Profit and Gross Margins (Third Quarter of 2025) $19.8 million and 42%, compared to $17.2 million and 41% in the third quarter of 2024. The improvement is attributed to the continued improvement of product sales mix and commercial scale.
Gross Profit and Gross Margins (First 9 Months of 2025) $59.4 million and 44%, compared to $52.9 million and 43% in the first 9 months of 2024. The increase is in line with the overall improvement in product sales mix and commercial scale.
Operating Expenses (First 9 Months of 2025) $36.8 million, compared to $38 million in the first 9 months of 2024. The decrease is mainly related to a reduction in R&D expenses due to development project timing changes.
Net Income (Third Quarter of 2025) $5.3 million or $0.09 per diluted share, up 37% compared to the third quarter of 2024.
Net Income (First 9 Months of 2025) $16.6 million or $0.29 per diluted share, up 56% compared to the first 9 months of 2024.
Adjusted EBITDA (Third Quarter of 2025) $11.7 million, up 34% over the third quarter of 2024.
Cash Provided by Operations (First 9 Months of 2025) $17.9 million, contributing to a strong cash position of $72 million at the end of the quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Anti-rabies immunoglobulin KEDRAB: Continued strong performance in the U.S. market through collaboration with Kedrion, with a firm commitment to minimum orders for 2025-2027. Sales are also growing in international markets such as Canada, Latin America, and Asia.
Anti-CMV immunoglobulin CYTOGAM: Initiated a comprehensive post-marketing research program, including the SHIELD study, to explore its benefits in CMV disease management for high-risk kidney transplant recipients.
Biosimilar products: Following the launch of the first biosimilar in Israel, two additional biosimilars are set to launch soon, with a pipeline for future launches. Expected to generate $15-$20 million in annual sales within five years.
Inhaled alpha-1 antitrypsin therapy (InnovAATe trial): Ongoing Phase III clinical trial with an interim futility analysis expected by the end of the quarter.
GLASSIA: Increased sales in ex-U.S. markets, particularly in Latin America and the CIS region. Continues to generate royalty income in the U.S. and Canada through Takeda.
Plasma collection centers: Ramping up operations at Houston and San Antonio centers, with FDA approval for Houston and expected approval for San Antonio in early 2026. Each center is projected to generate $8-$10 million annually at full capacity.
Revenue growth: Total revenues for the first 9 months of 2025 were $135.8 million, an 11% increase year-over-year. Adjusted EBITDA grew by 35% to $34.2 million.
Cost management: Operating expenses decreased slightly due to reduced R&D expenses, contributing to improved profitability.
Business development and M&A: Active due diligence on potential commercial targets, with plans for in-licensing, collaborations, and M&A transactions in early 2026 to enhance the product portfolio.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: The San Antonio plasma collection site is awaiting FDA approval, expected in early 2026. Additionally, subsequent inspections and approvals from the European Medicine Agency (EMA) are required for both plasma collection sites. Delays or failure in obtaining these approvals could impact operations and revenue generation.
Product-Specific Risks: CYTOGAM's post-marketing research program aims to demonstrate its advantages in CMV disease management. However, the lack of recent clinical data on CYTOGAM's benefits poses a challenge to its market adoption and growth potential.
Royalty Income Decline: GLASSIA's royalty income has declined due to a reduction in the royalty rate, which could impact overall revenue growth despite increased sales in other areas.
Strategic Execution Risks: The company is conducting due diligence on potential M&A and in-licensing opportunities. Failure to secure compelling transactions or integrate them effectively could hinder long-term growth objectives.
Plasma Collection Operations: The Houston and San Antonio plasma centers are ramping up operations, but achieving full capacity and securing long-term sales agreements for normal source plasma remain critical challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Annual Revenue Guidance: Kamada reiterates its annual revenue guidance of $178 million to $182 million for 2025, representing double-digit growth over 2024 results.
Adjusted EBITDA Guidance: The company maintains its adjusted EBITDA guidance of $40 million to $44 million for 2025, reflecting significant profitability growth.
Biosimilar Product Launches: Kamada plans to launch two additional biosimilars in the coming months, with expectations of annual sales of $15 million to $20 million within the next five years.
Business Development and M&A: The company anticipates securing in-licensing, collaboration, and/or M&A transactions in early 2026 to enhance its portfolio and support long-term growth.
Plasma Collection Centers: Kamada's Houston plasma center has received FDA approval, and the San Antonio center is expected to follow in early 2026. Each center is projected to generate $8 million to $10 million in annual revenues at full capacity.
Phase III InnovAATe Clinical Trial: The company is advancing its pivotal Phase III InnovAATe clinical trial for inhaled alpha-1 antitrypsin therapy, with interim futility analysis results expected by the end of Q4 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the difference between the current treatment population of CYTOGAM and the SHIELD study?
A:The current treatment population of CYTOGAM is primarily used prophylactically at the time of transplantation for high-risk patients or as part of treatment for active disease shortly after transplantation. The SHIELD study will test CYTOGAM for late CMV after patients have been treated for a few months with antivirals, focusing on prophylactic usage during the trimming down of antiviral usage.
Q:What is the status of enrollment for the ATD study and its timeline?
A:Enrollment is at 60%-65% of the reduced sample size. Recruitment has been challenging due to the orphan disease nature and placebo arm. Futility analysis results are expected by the end of the year, and recruitment is expected to complete by early 2027, with top-line results anticipated in the first half of 2029.
Q:What is driving the growth in the distribution business, and are the numbers sustainable?
A:The growth is driven by the addition of new products to the portfolio, including biosimilars and other distributed products. This growth is based on actual usage, not stocking orders, and is expected to continue and grow over the next few years.
Q:What is the status of plasma collection in Texas, and when will it meet proprietary product needs?
A:Specialty plasma collection is ramping up, with the Beaumont site dedicated to specialty plasma. Currently, the majority of plasma needs are met through external suppliers. Over time, self-collection will increase, but full independence is not expected as the company plans to maintain multiple suppliers for risk management.
Q:How will the interim data for the AATD treatment trial be released?
A:The futility analysis will be conducted by the end of the year, and results will be shared publicly through a press release. The analysis will be a go/no-go decision based on predefined success thresholds.
Q:What are the significant growth drivers for CYTOGAM and the overall business?
A:Growth is driven by a diverse portfolio, including GLASSIA sales in international markets, VARIZIG in the U.S., and the Israel distribution business. CYTOGAM sales have been below plan due to inventory management, hospital formulary additions, and fewer transplants, but growth is expected to resume in the coming months.
Q:What is the outlook for GLASSIA royalties?
A:Starting mid-August, royalties are at 6% of Takeda's net market sales in the U.S. and Canada, continuing until 2040. Royalties are expected to exceed $10 million in 2026 and grow at a single-digit rate annually thereafter. The company has alternative revenue sources to compensate for reduced royalties.
Q:What is the status of business development (BD) activities and the timeline for a transaction?
A:Active due diligence is ongoing for several potential commercial targets. A transaction is expected to be secured in early 2026. The longer timeline is due to thorough due diligence to ensure the right fit for Kamada's capabilities and resources.
Q:Review of Unclear Management Responses
A:Management avoided providing specific percentages for the late CMV population in the SHIELD study, stating they would check and get back with the information. Additionally, they did not provide detailed timelines or specifics on when plasma collection in Texas would fully meet proprietary product needs, emphasizing gradual progress and risk management strategies.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AAT IV
Agency EMA
America CIS
Amir investor
Antonio plasma
Antonio site
CEO Amir
CIS region
CMV disease
CMV donor
CMV infection
CMV kidney
CMV risk
CYTOGAM activity
CYTOGAM conclusion
CYTOGAM initiation
Canada country
EMA site
European
Phase III
SHIELD
addition
agreement
approval
benefit CYTOGAM
enrollment
facility
immunoglobulin
investigator
kidney transplant
others
plasma center
product market
program product
specialty
transplant recipient
KMDA Transcript
Kamada Ltd. (KMDA) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call presents mixed signals: while there's a positive revenue growth outlook for 2026 and dividend declaration, current financials show a gross margin decline and economic uncertainties. The Q&A session didn't reveal any major concerns, but competitive pressures and regulatory delays pose risks. Without a market cap, assuming moderate impact, the overall sentiment remains neutral, balancing positive long-term guidance against short-term challenges.
Kamada Ltd. (KMDA) Q4 2025 Earnings Call Transcript
Positive3-11
The earnings call reveals strong financial performance with a 12% revenue increase and 23% EBITDA growth. The company maintains its guidance, indicating confidence in future growth. The dividend declaration and plans for biosimilar launches further support a positive outlook. While gross margins slightly declined, the overall financial health remains robust. The Q&A section addresses concerns effectively, reinforcing management's confidence. Given the positive financial metrics, strategic plans, and shareholder returns, the stock price is likely to see a positive movement in the short term.
Kamada Ltd. (KMDA) Q3 2025 Earnings Call Transcript
Positive11-10
The earnings call indicates solid financial performance with increased revenues, net income, and EBITDA. Positive guidance, ongoing product launches, and strategic initiatives like M&A and plasma expansion further bolster growth prospects. While some uncertainties exist (e.g., CMV study specifics), the overall sentiment is positive, supported by strong financials and strategic plans.
Kamada Ltd. (KMDA) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call reflects strong financial metrics, with revenue and net income growth, disciplined expense management, and a solid cash position. The company's strategic initiatives, including biosimilar launches and plasma collection expansion, are promising. While some analyst concerns about competitive landscape and vague responses on funding were noted, the overall sentiment remains positive. The reiteration of 2025 guidance and a robust product portfolio further support a positive outlook. Given the lack of market cap data, a moderate positive reaction is expected, likely resulting in a 2% to 8% stock price increase.
KMDA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
